Table 2.
Univariable and multivariable analysis for PSA progression-free survival in patients with mHSPC treated with ADT
| Multivariable | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Model I (Base line PSA adjusted) (n = 52; chi-square 45.5; AIC 229.7) | Model II (n = 52; chi-square 13.2; AIC 234.7) | ||||||||
| Factors | Group | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value |
| Age | Continuous | 0.99 | 0.95–1.03 | 0.642 | ||||||
| ECOG-PS | 1 vs 0 | 1.13 | 0.40–3.17 | 0.820 | ||||||
| Log-transformed baseline PSA level (ng/dL) | Continuous | 1.14 | 0.95–1.36 | 0.156 | 3.62 | 1.57–8.36 | 0.003 | |||
| Baseline Hb level (g/dl) | Low vs normal | 3.31 | 1.68–6.51 | 0.001 | ||||||
| Baseline ALP level (IU/l) | High vs normal | 1.58 | 0.84–2.972 | 0.157 | ||||||
| Baseline LDH level (IU/l) | High vs normal | 1.23 | 0.66–2.29 | 0.510 | ||||||
| Presence of bone pain | Yes vs No | 1.52 | 0.81–2.84 | 0.191 | ||||||
| Biopsy Gleason score | ≥8 vs ≤7 | 2.60 | 0.62–10.82 | 0.190 | ||||||
| Visceral metastasis | Yes vs No | 28.62 | 4.03–203.21 | 0.001 | ||||||
| EOD score | ≥3 vs ≤2 | 3.89 | 1.91–7.92 | <0.001 | 3.14 | 1.45–6.82 | 0.004 | 3.47 | 1.65–7.33 | 0.001 |
| Sub-group in the CHAARTED trial | high vs low | 2.44 | 1.28–4.65 | 0.007 | ||||||
| Log-transformed PSA change (baseline-12wks) | Continuous | 1.10 | 0.92–1.32 | 0.281 | 0.30 | 0.13–0.68 | 0.004 | 1.04 | 0.87–1.25 | 0.66 |
| Hb level at 12 weeks | Low vs normal | 1.94 | 1.02–3.67 | 0.043 | ||||||
| ALP level at 12 weeks | High vs normal | 3.19 | 1.67–6.11 | 0.001 | ||||||
| LDH level at 12 weeks | High vs normal | 1.17 | 0.59–2.31 | 0.652 | ||||||
mHSPC metastatic hormone-sensitive prostate cancer, ADT androgen deprivation therapy, ECOG Eastern Cooperative Oncology Group, PSA prostate specific antigen, Hb hemoglobin, ALP Alkaline phosphatase, LDH Lactate dehydrogenase, EOD extend of bone metastasis, HR hazard ratio, CI confidence interbal